Di Federico A.; Mosca M.; Pagani R.; Carloni R.; Frega G.; De Giglio A.; Rizzo A.; Ricci D.; Tavolari S.; Di Marco M.; Palloni A.; Brandi G., Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes, «CANCERS», 2022, 14, Article number: 2429 , pp. 1 - 14 [Scientific article]Open Access
Alessandro Di Federico, Mirta Mosca, Rachele Pagani, Riccardo Carloni, Giorgio Frega, Andrea De Giglio, Alessandro Rizzo, Dalia Ricci, Simona Tavolari, Mariacristina Di Marco, Andrea Palloni, Giovanni Brandi., Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes, «CANCERS», 2022, 14, Article number: 2429 , pp. 1 - 14 [Scientific article]Open Access
De Giglio, Andrea; Aprile, Marta; Di Federico, Alessandro; Sperandi, Francesca; Melotti, Barbara; Gelsomino, Francesco; Ardizzoni, Andrea, Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC), «INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES», 2022, 23, pp. 10292 - 10299 [Scientific article]Open Access
De Giglio, Andrea; Grandinetti, Valeria; Aprile, Marta; Borelli, Greta; Campus, Anita; Croci Chiocchini, Anna Laura; Busutti, Marco; Vischini, Gisella; Di Federico, Alessandro; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea; La Manna, Gaetano; Gelsomino, Francesco, Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience, «LUNG CANCER», 2022, 174, pp. 91 - 96 [Scientific article]
Sisi, Monia; Fusaroli, Michele; De Giglio, Andrea; Facchinetti, Francesco; Ardizzoni, Andrea; Raschi, Emanuel; Gelsomino, Francesco, Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System, «TARGETED ONCOLOGY», 2022, 17, pp. 43 - 51 [Scientific article]Open Access
De Giglio, Andrea; Tassinari, Elisa; Zappi, Arianna; Di Federico, Alessandro; Lenzi, Barbara; Sperandi, Francesca; Melotti, Barbara; Gelsomino, Francesco; Maltoni, Marco; Ardizzoni, Andrea, The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy, «CANCERS», 2022, 14, pp. 5845 - 5851 [Scientific article]Open Access
Tateo V.; Manuzzi L.; Parisi C.; De Giglio A.; Campana D.; Pantaleo M.A.; Lamberti G., An overview on molecular characterization of thymic tumors: Old and new targets for clinical advances, «PHARMACEUTICALS», 2021, 14, Article number: 316 , pp. 316 - 339 [Scientific article]Open Access
Ricciuti, B.; Lamberti, G.; Andrini, E.; Genova, C.; De Giglio, A.; Bianconi, V.; Sahebkar, A.; Chiari, R.; Pirro, M., Antibody–drug conjugates for lung cancer in the era of personalized oncology, «SEMINARS IN CANCER BIOLOGY», 2021, 69, pp. 268 - 278 [Scientific article]
De Giglio A.; Scorsetti M.; Franceschini D.; Massari F.; Ardizzoni A., Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approach, «EUROPEAN JOURNAL OF CANCER», 2021, 143, pp. 75 - 77 [Scientific article]
Banna, G. L.; Cortellini, A.; Cortinovis, D. L.; Tiseo, M.; Aerts, J. G. J. V.; Barbieri, F.; Giusti, R.; Bria, E.; Grossi, F.; Pizzutilo, P.; Berardi, R.; Morabito, A.; Genova, C.; Mazzoni, F.; Di Noia, V.; Signorelli, D.; Gelibter, A.; Macerelli, M.; Rastelli, F.; Chiari, R.; Rocco, D.; Gori, S.; De Tursi, M.; Di Marino, P.; Mansueto, G.; Zoratto, F.; Filetti, M.; Montrone, M.; Citarella, F.; Marco, R.; Cantini, L.; Nigro, O.; D'Argento, E.; Buti, S.; Minuti, G.; Landi, L.; Guaitoli, G.; Lo Russo, G.; De Toma, A.; Donisi, C.; Friedlaender, A.; De Giglio, A.; Metro, G.; Porzio, G.; Ficorella, C.; Addeo, A., Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078] (ESMO Open (2021) 6(2), (S205970292100034X), (10.1016/j.esmoop.2021.100078)), «ESMO OPEN», 2021, 6, Article number: 100137 , pp. 1 - 1 [Scientific article]Open Access
Di Federico, A.; Nuvola, G.; Deiana, C.; Donati, G.; De Giglio, A., IMpower 132: Is the Second Exception to the Rule No Longer an Exception?, «JOURNAL OF THORACIC ONCOLOGY», 2021, 16, pp. 29 - 30 [Scientific article]
Dall'Olio F.G.; Gelsomino F.; Conci N.; Marcolin L.; De Giglio A.; Grilli G.; Sperandi F.; Fontana F.; Terracciano M.; Fragomeno B.; Tober N.; Manferrari G.; Brocchi S.; Golfieri R.; Fiorentino M.; Ardizzoni A., PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors, «CLINICAL LUNG CANCER», 2021, 22, pp. 423 - 431 [Scientific article]
Di Federico A.; De Giglio A.; Nuvola G.; Deiana C.; Conci N.; Gelsomino F.; Ardizzoni A., PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis, «FUTURE ONCOLOGY», 2021, 17, pp. 4415 - 4424 [Scientific article]
Di Federico A.; De Giglio A.; Parisi C.; Gelsomino F.; Ardizzoni A., PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2021, 160, Article number: 103302 , pp. 1 - 5 [Scientific article]
De Giglio A.; Di Federico A.; Gelsomino F.; Ardizzoni A., Prognostic relevance of pleural invasion for resected NSCLC patients undergoing adjuvant treatments: A propensity score-matched analysis of SEER database, «LUNG CANCER», 2021, 161, pp. 18 - 25 [Scientific article]
